Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

The price-to-earnings ratio for Alkermes plc (NASDAQ:ALKS) is 9.65. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Alkermes plc last week announced it had completed the sale of its development and manufacturing facility in Athlone, to Novo Nordisk. The Chief Executive Officer of Alkermes, Richard Pops, paid ...

The volatility ratio for the week is 2.98%, and the volatility levels for the last 30 days are 2.94% for Alkermes plc The simple moving average for the past 20 days is 0.53% for ALKS’s stock, with a ...

Throughout the last three months, 7 analysts have evaluated Alkermes ALKS, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings ...

DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk.

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility ...